🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Methenamine Hippurate Following Intradetrusor OnabotulinumtoxinA Injection

RecruitingPhase 4Ages 18 Years - anyFemaleWomen and Infants Hospital of Rhode Island
NCT06953271 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The goal of this clinical trial is to compare methenamine hippurate prophylaxis to routine antibiotic prophylaxis following onabotulinumtoxinA (BOTOX-A) injections in women with overactive bladder (OAB). Participants will be randomly selected to receive one of the two post-procedural prophylaxis medications. The primary outcome measure will be urinary tract infection (UTI) rates within 30 days from the BOTOX-A procedure. Secondary outcomes will assess patient satisfaction with the two post-procedural prophylaxis medications.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * 18 years of age or older * undergoing intradetrusor BOTOX-A injections in the office setting for overactive bladder Exclusion Criteria: * cisgender male individuals * neurogenic reasons for bladder symptoms (i.e. spinal cord injury, multiple sclerosis, etc.) * known allergy and/or contraindication to methenamine hippurate * currently already taking methenamine hippurate at the time of the procedure * taking antibiotics for any reason on the day of their BOTOX-A procedure * positive UTI at time of procedure (positive dip at time of procedure) * history of bladder cancer * history of pelvic radiation * surgically altered detrusor muscle * pre-procedural need for catheterization * diagnosis of Interstitial Cystitis/Painful Bladder Syndrome (IC/PBS) * pregnant or lactating individuals
💊

What it tests

  • Methenamine Hippurate
  • Typically prescribed oral antibiotic prophylaxis
📍

Where

1 site
Women & Infants Hospital
Providence, United States
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy